The alpha 2-adrenergic system of the platelet in cystic fibrosis.
The ability of norepinephrine to inhibit prostaglandin E1 (PGE1)-stimulated accumulation of adenosine 3':5' cyclic monophosphate (cyclic AMP) in intact washed platelets was determined in 12 patients with cystic fibrosis, 6 parents of patients with cystic fibrosis, and a total of 21 healthy age-matched controls. Patients with cystic fibrosis and their parents did not differ from their age-matched controls in basal or PGE1-stimulated levels of cyclic AMP, nor in the dose dependent inhibition of cAMP accumulation by norepinephrine. Moreover, binding sites for [3H]-dihydroergocryptine were present in normal numbers and had normal ligand affinity in platelet membranes from patients with cystic fibrosis. In all measures tested, the alpha 2-adrenergic system in the platelet was normal in cystic fibrosis.
D000293:Adolescent; D000328:Adult; D000527:Alprostadil; D001792:Blood Platelets / Q000187:drug effects / Q000378:metabolism*; D000242:Cyclic AMP / Q000097:blood; D003550:Cystic Fibrosis / Q000097:blood* / Q000503:physiopathology; D004088:Dihydroergotoxine / Q000097:blood; D006801:Humans; D066298:In Vitro Techniques; D008875:Middle Aged; D009638:Norepinephrine / Q000494:pharmacology; D011458:Prostaglandins E / Q000037:antagonists & inhibitors; D011942:Receptors, Adrenergic, alpha / Q000187:drug effects / Q000378:metabolism*
D011458:Prostaglandins E; D011942:Receptors, Adrenergic, alpha; D004088:Dihydroergotoxine; D000242:Cyclic AMP; D000527:Alprostadil; D009638:Norepinephrine